These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30731098)

  • 1. Multiscale modelling of cancer response to oncolytic viral therapy.
    Alzahrani T; Eftimie R; Trucu D
    Math Biosci; 2019 Apr; 310():76-95. PubMed ID: 30731098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonlocal multiscale modelling of tumour-oncolytic viruses interactions within a heterogeneous fibrous/non-fibrous extracellular matrix.
    Alsisi A; Eftimie R; Trucu D
    Math Biosci Eng; 2022 Apr; 19(6):6157-6185. PubMed ID: 35603396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiscale moving boundary modelling of cancer interactions with a fusogenic oncolytic virus: The impact of syncytia dynamics.
    Alzahrani T; Eftimie R; Trucu D
    Math Biosci; 2020 May; 323():108296. PubMed ID: 31887267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-local multiscale approach for the impact of go or grow hypothesis on tumour-viruses interactions.
    Alsisi A; Eftimie R; Trucu D
    Math Biosci Eng; 2021 Jun; 18(5):5252-5284. PubMed ID: 34517487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Scale Degradation of Peritumoural Extracellular Matrix Fibre Network and Its Role Within Tissue-Scale Cancer Invasion.
    Shuttleworth R; Trucu D
    Bull Math Biol; 2020 May; 82(6):65. PubMed ID: 32458057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multiscale Mathematical Model of Tumour Invasive Growth.
    Peng L; Trucu D; Lin P; Thompson A; Chaplain MA
    Bull Math Biol; 2017 Mar; 79(3):389-429. PubMed ID: 28210916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic viral therapies and the delicate balance between virus-macrophage-tumour interactions: A mathematical approach.
    Almuallem N; Trucu D; Eftimie R
    Math Biosci Eng; 2020 Dec; 18(1):764-799. PubMed ID: 33525118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of control theory in a delayed-infection and immune-evading oncolytic virotherapy.
    Lee T; Jenner AL; Kim PS; Lee J
    Math Biosci Eng; 2020 Feb; 17(3):2361-2383. PubMed ID: 32233540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Questing for an optimal, universal viral agent for oncolytic virotherapy.
    Paiva LR; Martins ML; Ferreira SC
    Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Oct; 84(4 Pt 1):041918. PubMed ID: 22181186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.
    Fillat C; Maliandi MV; Mato-Berciano A; Alemany R
    Curr Pharm Des; 2014; 20(42):6513-21. PubMed ID: 25341928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of a mathematical model for tumor therapy with a fusogenic oncolytic virus.
    Jacobsen K; Pilyugin SS
    Math Biosci; 2015 Dec; 270(Pt B):169-82. PubMed ID: 25744606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
    Power AT; Bell JC
    Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the treatment of melanoma: A mathematical model of oncolytic virotherapy.
    Ramaj T; Zou X
    Math Biosci; 2023 Nov; 365():109073. PubMed ID: 37660975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
    Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
    Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study.
    Pooladvand P; Yun CO; Yoon AR; Kim PS; Frascoli F
    Math Biosci; 2021 Apr; 334():108520. PubMed ID: 33290764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
    Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
    Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy.
    Burchett R; Walsh S; Wan Y; Bramson JL
    Cytokine Growth Factor Rev; 2020 Dec; 56():149-159. PubMed ID: 32665126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.